Dataset from Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Influenza Vaccine GSK1247446A With Various Formulations in Subjects Aged 18-64 Years

In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 18-64 years.

为筛选出可最大化提升免疫应答且同时维持可接受安全谱的疫苗配方，本研究拟评估葛兰素史克生物制品（GSK Biologicals）旗下不同配方流感疫苗在18至64岁成人受试者中的免疫原性、安全性与反应原性。